Dendritic cell vaccine

Dendritic cell vaccine has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 15, 2026: “Older mice with brain tumors had poorer immune-cell drainage”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on dendritic cell vaccine

At a glance

The findings reach cells, none yet in people. 1 lab in 1 country.

Cells: a single group. Worms or flies, mice and humans: nothing yet.
  • 1 lab in 1 country
  • Animals1

What did studies of dendritic cell vaccine find?

1

Studies of dendritic cell vaccine measured one outcome, OT-I T cell activation.

OT-I T cell activation

upin mouse cells1

1 study
  1. Dendritic cell vaccine activates OT-I T cell activation in mouse cells (dendritic cell vaccines pulsed with SIINFEKL peptide).

    “when pulsed with SIINFEKL peptide, aged DCV efficiently activate OT-I T cells.”

    Cellsdendritic cell vaccines pulsed with SIINFEKL peptideT cell

    Older mice with brain tumors had poorer immune-cell drainage

    Neuro-Oncology

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
Neuro-Oncology

Older mice with brain tumors had poorer immune-cell drainage

Brain-tumor experiments compared mice aged 85–90 weeks with mice aged 6–8 weeks; older mice had shorter survival and signs suggesting impaired drainage around the brain.Brain-tumor experiments compared mice aged 85–90 weeks with mice aged 6–8 weeks; older mice had shorter survival and signs suggesting impaired drainage around the brain.

Mouse studyImmune response